TORONTO, Nov. 10, 2025 (GLOBE NEWSWIRE) — Carbon Streaming Corporation (Cboe CA: NETZ) (OTCQB: OFSTF) (FSE: M2Q) (“Carbon Streaming” or the “Company”) today reported its financial results for the three and nine months ended September 30, 2025. All figures are expressed in United States dollars, unless otherwise indicated. Carbon Streaming Chief Executive Officer Marin Katusa stated: “In the third quarter of 2025, Carbon Streaming continued to strengthen its financial position and focus on maximizing value from its existing portfolio. During the quarter, we achieved positive operating cash flow, reflecting the success of our cost reduction initiatives and continued progress in generating cash from our stream and royalty agreements. We also successfully implemented the terms of the InfiniteEARTH settlement, delivering cash proceeds...

– $169.7 million revenue, up 173.6% year-over-year– $43.0 million adjusted EBITDA, up from negative $7.9 million last year– Expanding and accelerating AI strategy across multiple initiatives– Achieved 41.2 EH/s of self-mining at the end of October, 2025– Commenced SEALMINER A3 mass production– Early SEAL04 samples have demonstrated 6-7 J/TH power efficiency at the chip level under low-voltage, ultra-power saving mode SINGAPORE, Nov. 10, 2025 (GLOBE NEWSWIRE) — Bitdeer Technologies Group (NASDAQ: BTDR) (“Bitdeer” or the “Company”), a world-leading technology company for Bitcoin mining and AI cloud, today released its unaudited financial results for the third quarter ended September 30, 2025. Q3 2025 Financial HighlightsAll amounts compared to Q3 2024 unless otherwise notedTotal revenue was US$169.7...

Revenue increased 36.7% year-over-year to $49.3 million in Q3 2025 and grew 29.0% excluding the impact of the Keystone acquisition  Net loss increased to $(9.7) million in Q3 2025 versus $(5.6) million in the prior year period Medical Segment Adjusted EBITDA increased 93.5% in Q3 2025 to $7.6 million versus the prior year period and increased 80.2% excluding the impact of the Keystone acquisition(1) Medical Segment Adjusted EBITDA margin excluding Keystone increased to 15.1% in Q3 2025(1) Raised 2025 revenue guidance to $185-195 million, reaffirmed Adjusted EBITDA range Investor Day scheduled for November 17th 2025; will introduce 2026 guidance and medium term financial targetsNEW YORK, Nov. 10, 2025 (GLOBE NEWSWIRE) — Strata Critical Medical, Inc. (Nasdaq: SRTA, “Strata” or the “Company”), today announced...

In vivo preclinical proof-of-concept data presented at AHA and ESGCT demonstrating >90% LDL-C reduction in non-human primates supports EDIT-401’s potential as a best-in-class, one-time therapy Company on track to submit IND/CTA for EDIT-401 by mid-2026 and achieve initial human proof-of-concept data by year-end 2026 Extended cash runway into the third quarter of 2027, enabling progression of EDIT-401 beyond initial human proof-of-concept data CAMBRIDGE, Mass., Nov. 10, 2025 (GLOBE NEWSWIRE) — Editas Medicine, Inc. (Nasdaq: EDIT), a pioneering gene editing company focused on developing transformative medicines for serious diseases, today reported financial results for the third quarter 2025 and provided business updates. “We are incredibly excited by the progress we made in the third quarter advancing our lead in vivo development...

BASEL, Switzerland and LONDON and NEW YORK, Nov. 10, 2025 (GLOBE NEWSWIRE) — Roivant (Nasdaq: ROIV) today reported its financial results for the second quarter ended September 30, 2025, and provided a business update.Brepocitinib 30 mg demonstrated clinically meaningful and statistically significant improvement compared to placebo on the primary endpoint and all nine key secondary endpoints in Phase 3 VALOR study in dermatomyositis (DM), with NDA filing planned for the first half of calendar year 2026Brepocitinib program continues to advance with rapid enrollment in Phase 3 study in non-infectious uveitis (NIU) and proof-of-concept trial in cutaneous sarcoidosis (CS), with readouts expected in the first half of calendar year 2027 and second half of calendar year 2026, respectivelyImmunovant study in uncontrolled Graves’ disease...

Aligned with U.S Food and Drug Administration (FDA) on design of planned Phase 3 clinical trial of neflamapimod in patients with dementia with Lewy bodies (DLB) Reported 32-week data from Phase 2b RewinD-LB trial showing neflamapimod treatment in patients with DLB had a durable beneficial effect on clinical progression and resulted in substantial reductions in plasma levels of a well-established biomarker of neurodegeneration Meeting with global regulators in coming months and preparing for global pivotal trial initiation in second half of 2026 Initial biomarker data from Phase 2a trial in a sub-type of frontotemporal dementia (FTD) and topline results from Phase 2a trial in recovery after stroke expected in 2026 BOSTON, Nov. 10, 2025 (GLOBE NEWSWIRE) — CervoMed Inc. (NASDAQ: CRVO), a clinical stage company focused on developing...

Third quarter revenues totaled $575 millionThird quarter GAAP consolidated loss from continuing operations of $20 millionAdjusted EBITDA in Q3 totaled $74 millionEntered into amended credit agreement that enables the Company to potentially execute certain strategic alternatives and strengthens the Company’s financial flexibility2025 Adjusted EBITDA now expected to be within a range of $268 million to $278 million and free cash flow expected to be within a range of $(30) million to $(20) millionPHILADELPHIA, Nov. 10, 2025 (GLOBE NEWSWIRE) — Enviri Corporation (NYSE: NVRI) (the “Company”) today reported third quarter 2025 results. Revenues in the third quarter of 2025 totaled $575 million, and on a U.S. GAAP (“GAAP”) basis, the consolidated loss from continuing operations was $20 million. Adjusted...

Consolidated Net Sales Increased 21% YoY to $66.7 Million; International Export Sales Increased 758% Consolidated Net Income from Continuing Ops of $10.8 Million or $0.09 Per Share, Up YoY and Sequentially  Consolidated Adjusted EBITDA of $20.2 Million or 30.3% of Sales; Both Company Records Operating Cash Flow of $24.4 Million Brings YTD Total to $46.7 Million; Company Ends Quarter with Approximately $88 Million in Cash Canadian Cannabis Delivers Record Net Sales, Record Gross Margin of 56%, Record Adj. EBITDA and Record Cash Flow from Operations; 40 Metric Ton Production Capacity Expansion Underway Continued Momentum in Netherlands Cannabis Sales as Capacity Expansion Progresses on ScheduleVANCOUVER, British Columbia, Nov. 10, 2025 (GLOBE NEWSWIRE) — Village Farms International, Inc. (“Village Farms” or the “Company”) (NASDAQ:...

Net Contribution grew by 28% year-over-year to $215 millionAssets Under Administration grew by 76% year-over-year to $20.8 billionFunded accounts grew by 16% year-over-year to 3.73 millionAnnounced a $150 million share repurchase program NEW YORK, Nov. 10, 2025 (GLOBE NEWSWIRE) — eToro Group Ltd. (“eToro”, or the “Company”) (NASDAQ: ETOR), the trading and investing platform, today announced financial results for the third quarter ended September 30, 2025. “We  remain focused on executing our strategy across our four  key pillars of trading, investing, wealth management, and neo-banking, developing new products and services that deliver value to users across every step of their investing journey. This robust product offering, combined with our unique shared social experience for users worldwide, creates a powerful flywheel that...

(All dollar amounts are expressed in Canadian dollars, unless stated otherwise) HIGHLIGHTS Q3 2025 (at September 30, 2025)~$401.4 million in cash and cash equivalents Drawn ~$137.2 million (US$100.0 million) under the US$450 million Appian financing facility executed during the quarter Completed private placements for ~$280.4 million (US$203.1 million) in gross proceeds Advanced pre-construction activities and underground mine development activities, and announced results of ore sorting and drilling programs at the permitted Cariboo Gold Project Sold 877 ounces of gold from the Tintic small-scale heap leach projectSubsequent to Q3 2025Completed an additional private placement for ~$82.5 million in gross proceeds Released infill drill results from the ongoing program at Cariboo; appointed Scott Smith as VP, ExplorationMONTREAL,...